Investigation of the Effect of Fasting Duration and Temporary Withholding of Subcutaneous Administration of Zenagamtide on Retained Gastric Contents in Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Novo Nordisk A/S
Summary
The purpose of this clinical study is to find out how the duration of fasting (not eating or drinking, except for water) and pausing of treatment with zenagamtide medication affect the amount of food and liquid left in the stomach of people using zenagamtide.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 and older at the time of signing the informed consent. * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator. For participants with type 2 diabetes (T2D) * Diagnosed with type 2 diabetes (T2D) more than (\>) 180 days before screening. * No treatment with oral anti-diabetic drugs except metformin. Treatment with met…
Interventions
- DrugZenagamtide
Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors in one of the body parts: thigh, abdomen or upper arm.
Location
- Altasciences Clinical LA, Inc.Cypress, California